CO6180425A2 - Antagonista del receptor de angiotensina ii para la prevencion o el tratamiento de enfermedades generalizadas en gatos - Google Patents
Antagonista del receptor de angiotensina ii para la prevencion o el tratamiento de enfermedades generalizadas en gatosInfo
- Publication number
- CO6180425A2 CO6180425A2 CO09035442A CO09035442A CO6180425A2 CO 6180425 A2 CO6180425 A2 CO 6180425A2 CO 09035442 A CO09035442 A CO 09035442A CO 09035442 A CO09035442 A CO 09035442A CO 6180425 A2 CO6180425 A2 CO 6180425A2
- Authority
- CO
- Colombia
- Prior art keywords
- angiotensin
- receptor
- antagonist
- use according
- generalized
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
1.- Utilización de un antagonista (sartán) del receptor 1 (AT-1) de angiotensina II para la preparación de una composición farmacéutica que comprende una cantidad terapéuticamente eficaz de dicho antagonista del receptor 1 (AT-1) de angiotensina II para el tratamiento de una enfermedad generalizada en gatos. 2.- La utilización según la reivindicación 2, en la que la enfermedad generalizada se selecciona del grupo de cardiovasculares enfermedades, tales como la cardiomiopatía dilatada (DCM), insuficiencia de la válvula mitral (MI), cardiomiopatía hipertrófica (HCM) y otras cardiopatías adquiridas o hereditarias, hipertensión generalizada, nefropatía crónica y otras vasculopatías, trastornos metabólicos similares a la diabetes mellitus. 3.- La utilización según la reivindicación 1 o 2, en la que la enfermedad generalizada es la nefropatía crónica. 4.- La utilización según una cualquiera de las reivindicaciones 1 a 3, en la que el antagonista del receptor 1 (AT-1) de angiotensina II se selecciona del grupo consistente en: candesartán, eprosartán, irbesartán, losartán, tasosartán, telmisartán, valsartán, y una de sus sales farmacéuticamente aceptable. 5.- La utilización según una cualquiera de las reivindicaciones 1 a 4, en la que la cantidad terapéuticamente eficaz del antagonista del receptor 1 (AT-1) de angiotensina II es aproximadamente 0,01 a aproximadamente 5,0 mg/kg de peso corporal. 6.- La utilización según una cualquiera de las reivindicaciones 1 a 5, en la que la composición farmacéutica se administra a un sujeto que lo necesita por vía parenteral a una dosis de aproximadamente 0,01 a aproximadamente 1 mg de antagonista del receptor 1 (AT-1) de angiotensina II por kg de peso corporal o por vía oral, rectal, nasal o de inhalación en una dosis de aproximadamente 0,03 a aproximadamente 5,0 mg de antagonista del receptor 1 (AT-1) de angiotensina II por kg de peso corporal.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06121905A EP1908469A1 (en) | 2006-10-06 | 2006-10-06 | Angiotensin II receptor antagonist for the treatment of systemic diseases in cats |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6180425A2 true CO6180425A2 (es) | 2010-07-19 |
Family
ID=37744125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO09035442A CO6180425A2 (es) | 2006-10-06 | 2009-04-06 | Antagonista del receptor de angiotensina ii para la prevencion o el tratamiento de enfermedades generalizadas en gatos |
Country Status (25)
Country | Link |
---|---|
US (5) | US8772278B2 (es) |
EP (5) | EP1908469A1 (es) |
JP (5) | JP5425631B2 (es) |
KR (2) | KR101456151B1 (es) |
CN (6) | CN114344293B (es) |
AR (1) | AR063155A1 (es) |
BR (4) | BRPI0718041A2 (es) |
CA (1) | CA2665435C (es) |
CL (2) | CL2007002897A1 (es) |
CO (1) | CO6180425A2 (es) |
CY (2) | CY1114266T1 (es) |
DK (4) | DK2086535T3 (es) |
ES (4) | ES2562182T3 (es) |
HR (1) | HRP20130696T1 (es) |
HU (4) | HUE027280T2 (es) |
LU (1) | LU92282I2 (es) |
MX (4) | MX360150B (es) |
NL (1) | NL300616I2 (es) |
NZ (3) | NZ576109A (es) |
PL (4) | PL2420231T3 (es) |
PT (1) | PT2086535E (es) |
SI (1) | SI2086535T1 (es) |
TW (3) | TWI539950B (es) |
WO (1) | WO2008040774A2 (es) |
ZA (1) | ZA200901218B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1908469A1 (en) | 2006-10-06 | 2008-04-09 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin II receptor antagonist for the treatment of systemic diseases in cats |
AR068814A1 (es) * | 2007-08-29 | 2009-12-09 | Orion Corp | Composicion farmaceutica que comprende levosimendan y un inhibidor de la enzima conversina de la angiotensina (ace), y uso |
WO2010097501A2 (en) * | 2009-02-26 | 2010-09-02 | Orion Corporation | A combination treatment |
US8871795B2 (en) | 2009-05-20 | 2014-10-28 | Boehringer Ingleheim Vetmedica Gmbh | Pharmaceutical oral telmisartan solution |
CN102283832B (zh) * | 2011-09-09 | 2013-04-10 | 南京正宽医药科技有限公司 | 一种预防或治疗高血压肥胖患者的药物组合物及用途 |
SG10201703789QA (en) * | 2012-05-18 | 2017-06-29 | Luoda Pharma Pty Ltd | Liquid formulation |
DE102012018903A1 (de) | 2012-09-26 | 2014-03-27 | Elisabeth Kurth | Brustglocke für die manuelle Laktation von Milch aus der weiblichen Brust |
CN105233288A (zh) * | 2015-09-28 | 2016-01-13 | 青岛云天生物技术有限公司 | 一种治疗或预防肥胖型高血压的药物组合物及其用途 |
JP6800633B2 (ja) * | 2016-07-04 | 2020-12-16 | 株式会社カネカ | 非ヒト動物において腎機能の低下を抑制する方法 |
KR20200026975A (ko) * | 2017-07-07 | 2020-03-11 | 베링거잉겔하임베트메디카게엠베하 | 고양이에서 전신 질환의 예방 또는 치료를 위한 안지오텐신 ii 수용체 길항제 |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1023027B (de) | 1953-07-10 | 1958-01-23 | Hoffmann La Roche | Verfahren zur Herstellung von Polyendialdehyden |
JPS5671074A (en) | 1979-11-12 | 1981-06-13 | Takeda Chem Ind Ltd | 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative |
US4448778A (en) | 1981-08-03 | 1984-05-15 | Ici Americas Inc. | Maltitol containing gel base systems |
CA1334092C (en) | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
CA1338238C (en) | 1988-01-07 | 1996-04-09 | David John Carini | Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids |
US5015651A (en) | 1988-01-07 | 1991-05-14 | E. I. Du Pont De Nemours And Company | Treatment of hypertension with 1,2,4-angiotensin II antagonists |
US4880804A (en) | 1988-01-07 | 1989-11-14 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking benzimidazoles |
IE70593B1 (en) | 1989-09-29 | 1996-12-11 | Eisai Co Ltd | Biphenylmethane derivative the use of it and pharmacological compositions containing same |
ATE134624T1 (de) | 1990-02-19 | 1996-03-15 | Ciba Geigy Ag | Acylverbindungen |
NZ237476A (en) | 1990-03-20 | 1994-01-26 | Sanofi Sa | N-substituted heterocyclic compounds and pharmaceutical compositions. |
US5196444A (en) | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
IL99246A0 (en) | 1990-09-10 | 1992-07-15 | Abbott Lab | Angiotensin ii receptor antagonists and pharmaceutical compositions containing them |
GB9027210D0 (en) | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
US6028091A (en) | 1990-12-14 | 2000-02-22 | Smithkline Beecham Plc | Medicament |
US5591762A (en) | 1991-02-06 | 1997-01-07 | Dr. Karl Thomae Gmbh | Benzimidazoles useful as angiotensin-11 antagonists |
SI9210098B (sl) | 1991-02-06 | 2000-06-30 | Dr. Karl Thomae | Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo |
US5196537A (en) | 1991-03-21 | 1993-03-23 | G. D. Searle & Co. | 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders |
GB9110636D0 (en) | 1991-05-16 | 1991-07-03 | Glaxo Group Ltd | Chemical compounds |
EP0872235A1 (en) | 1992-04-13 | 1998-10-21 | Zeneca Limited | Therapeutic agents |
JP3862295B2 (ja) * | 1993-09-30 | 2006-12-27 | 独立行政法人理化学研究所 | 抗肥満剤 |
CA2186606A1 (en) | 1994-03-29 | 1995-10-05 | Edward B. Nelson | Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles |
EP0820302A1 (en) * | 1995-04-07 | 1998-01-28 | Novartis AG | Combination compositions containing benazepril or benazeprilat and valsartan |
EP0910375B1 (en) * | 1996-06-24 | 2002-05-02 | Merck & Co., Inc. | A composition of enalapril and losartan |
ATE258430T1 (de) | 1998-03-04 | 2004-02-15 | Takeda Chemical Industries Ltd | Zubereitung mit verzögerter wirkstoffabgabe für aii antagonisten, ihre herstellung und verwendung |
JPH11315034A (ja) * | 1998-03-04 | 1999-11-16 | Takeda Chem Ind Ltd | アンギオテンシンii拮抗作用を有する化合物の徐放性製剤、その製造法および用途 |
US6204281B1 (en) * | 1998-07-10 | 2001-03-20 | Novartis Ag | Method of treatment and pharmaceutical composition |
DE19901921C2 (de) | 1999-01-19 | 2001-01-04 | Boehringer Ingelheim Pharma | Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels |
US6358986B1 (en) | 1999-01-19 | 2002-03-19 | Boehringer Ingelheim Pharma Kg | Polymorphs of telmisartan |
DE10018401A1 (de) * | 2000-04-13 | 2001-10-25 | Boehringer Ingelheim Pharma | Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen |
AU2001294192A1 (en) * | 2000-10-06 | 2002-04-22 | Takeda Chemical Industries Ltd. | Solid preparations |
US20030073705A1 (en) | 2001-05-14 | 2003-04-17 | Shahnaz Shahinfar | Method of treatment |
CA2456034A1 (en) * | 2001-08-03 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Sustained-release medicines |
DE10153737A1 (de) | 2001-10-31 | 2003-05-28 | Boehringer Ingelheim Pharma | Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels |
US6737432B2 (en) | 2001-10-31 | 2004-05-18 | Boehringer Ingelheim Pharma Kg | Crystalline form of telmisartan sodium |
EP1509248A1 (en) * | 2002-05-17 | 2005-03-02 | Novartis AG | Combination of angiotensin ii receptor blocker and beta-blocker for secondary prevention of myocardial infarction |
US7232828B2 (en) | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
CA2497048A1 (en) * | 2002-08-28 | 2004-03-11 | Curis, Inc. | Conjoint administration of morphogens and ace inhibitors in treatment of chronic renal failure |
US8980870B2 (en) * | 2002-09-24 | 2015-03-17 | Boehringer Ingelheim International Gmbh | Solid telmisartan pharmaceutical formulations |
DE10244681A1 (de) | 2002-09-24 | 2004-04-08 | Boehringer Ingelheim International Gmbh | Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung |
DE10335027A1 (de) | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
WO2005070462A2 (en) * | 2004-01-12 | 2005-08-04 | Sepracor, Inc. | Compositions comprising (s)-amlodipine and an angiotensin receptor blocker and methods of their use |
DE102004008804A1 (de) * | 2004-02-20 | 2005-09-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Mehrschichttablette |
EP1579862A1 (en) * | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
WO2005123070A1 (en) * | 2004-06-09 | 2005-12-29 | Fibrogen, Inc. | Dual blockade of renin-angiotensin system reduces connective tissue growth factor levels in diabetic nephropathy |
CN1602960A (zh) * | 2004-07-23 | 2005-04-06 | 海南国栋药物研究所有限公司 | 一种防治心脑血管病及糖尿病等代谢综合症的复合制剂 |
CN100364532C (zh) * | 2004-09-30 | 2008-01-30 | 江苏恒瑞医药股份有限公司 | 包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物 |
ES2452019T5 (es) * | 2004-11-05 | 2021-06-28 | Boehringer Ingelheim Int | Comprimido bicapa que comprende telmisartán y amlodipino |
CN1813707A (zh) * | 2004-12-01 | 2006-08-09 | 鲁南制药集团股份有限公司 | 用于治疗高血压的含有单硝酸异山梨酯的药物组合物 |
US20070026026A1 (en) * | 2005-08-01 | 2007-02-01 | David Delmarre | Oral liquid losartan compositions |
EP1908469A1 (en) | 2006-10-06 | 2008-04-09 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin II receptor antagonist for the treatment of systemic diseases in cats |
EP1970053A1 (en) | 2007-03-14 | 2008-09-17 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pharmaceutical composition |
US8871795B2 (en) | 2009-05-20 | 2014-10-28 | Boehringer Ingleheim Vetmedica Gmbh | Pharmaceutical oral telmisartan solution |
-
2006
- 2006-10-06 EP EP06121905A patent/EP1908469A1/en not_active Ceased
-
2007
- 2007-10-04 PT PT78209087T patent/PT2086535E/pt unknown
- 2007-10-04 MX MX2013004349A patent/MX360150B/es unknown
- 2007-10-04 SI SI200731289T patent/SI2086535T1/sl unknown
- 2007-10-04 DK DK07820908.7T patent/DK2086535T3/da active
- 2007-10-04 PL PL11186070T patent/PL2420231T3/pl unknown
- 2007-10-04 ES ES11186078.9T patent/ES2562182T3/es active Active
- 2007-10-04 DK DK11186078.9T patent/DK2420232T3/en active
- 2007-10-04 MX MX2013004348A patent/MX360147B/es unknown
- 2007-10-04 BR BRPI0718041 patent/BRPI0718041A2/pt not_active Application Discontinuation
- 2007-10-04 CN CN202111463480.1A patent/CN114344293B/zh active Active
- 2007-10-04 MX MX2013004347A patent/MX360148B/es unknown
- 2007-10-04 NZ NZ576109A patent/NZ576109A/en unknown
- 2007-10-04 KR KR1020097009113A patent/KR101456151B1/ko active IP Right Grant
- 2007-10-04 CN CN201510336736.0A patent/CN105148272A/zh active Pending
- 2007-10-04 NZ NZ609533A patent/NZ609533A/en unknown
- 2007-10-04 BR BRBR122013019533-5A patent/BR122013019533A2/pt not_active Application Discontinuation
- 2007-10-04 EP EP11186080.5A patent/EP2420233B1/en active Active
- 2007-10-04 DK DK11186080.5T patent/DK2420233T3/en active
- 2007-10-04 BR BRBR122013019534-3A patent/BR122013019534A2/pt not_active Application Discontinuation
- 2007-10-04 WO PCT/EP2007/060531 patent/WO2008040774A2/en active Application Filing
- 2007-10-04 BR BRBR122013019535-1A patent/BR122013019535A2/pt not_active Application Discontinuation
- 2007-10-04 ES ES11186080.5T patent/ES2567041T3/es active Active
- 2007-10-04 CN CN201811093737.7A patent/CN109125730A/zh active Pending
- 2007-10-04 ES ES11186070.6T patent/ES2565519T3/es active Active
- 2007-10-04 ES ES07820908T patent/ES2425482T3/es active Active
- 2007-10-04 CN CN201210056647.7A patent/CN102580095B/zh active Active
- 2007-10-04 PL PL07820908T patent/PL2086535T3/pl unknown
- 2007-10-04 DK DK11186070.6T patent/DK2420231T3/en active
- 2007-10-04 EP EP11186070.6A patent/EP2420231B1/en active Active
- 2007-10-04 KR KR1020147014825A patent/KR101529541B1/ko active IP Right Grant
- 2007-10-04 JP JP2009530883A patent/JP5425631B2/ja active Active
- 2007-10-04 CN CN2011104188656A patent/CN102512678A/zh active Pending
- 2007-10-04 HU HUE11186078A patent/HUE027280T2/en unknown
- 2007-10-04 EP EP07820908.7A patent/EP2086535B1/en active Active
- 2007-10-04 NZ NZ597648A patent/NZ597648A/xx unknown
- 2007-10-04 PL PL11186078T patent/PL2420232T3/pl unknown
- 2007-10-04 CA CA2665435A patent/CA2665435C/en active Active
- 2007-10-04 HU HUE11186070A patent/HUE027399T2/en unknown
- 2007-10-04 EP EP11186078.9A patent/EP2420232B1/en active Active
- 2007-10-04 PL PL11186080T patent/PL2420233T3/pl unknown
- 2007-10-04 CN CN2007800374949A patent/CN101522191B/zh active Active
- 2007-10-04 MX MX2009002340A patent/MX2009002340A/es active IP Right Grant
- 2007-10-05 TW TW102133689A patent/TWI539950B/zh active
- 2007-10-05 TW TW096137618A patent/TWI415605B/zh active
- 2007-10-05 TW TW102114897A patent/TWI539949B/zh active
- 2007-10-05 CL CL200702897A patent/CL2007002897A1/es unknown
- 2007-10-05 US US11/973,250 patent/US8772278B2/en active Active
- 2007-10-09 AR ARP070104427A patent/AR063155A1/es active Pending
-
2009
- 2009-02-20 ZA ZA200901218A patent/ZA200901218B/xx unknown
- 2009-04-06 CO CO09035442A patent/CO6180425A2/es not_active Application Discontinuation
-
2012
- 2012-05-24 CL CL2012001349A patent/CL2012001349A1/es unknown
-
2013
- 2013-03-13 US US13/799,768 patent/US9308197B2/en active Active
- 2013-07-23 HR HRP20130696TT patent/HRP20130696T1/hr unknown
- 2013-08-01 JP JP2013160675A patent/JP6151123B2/ja active Active
- 2013-08-01 JP JP2013160676A patent/JP5899165B2/ja active Active
- 2013-08-21 CY CY20131100712T patent/CY1114266T1/el unknown
- 2013-09-18 NL NL300616C patent/NL300616I2/nl unknown
- 2013-09-18 CY CY2013037C patent/CY2013037I1/el unknown
- 2013-09-19 LU LU92282C patent/LU92282I2/fr unknown
- 2013-10-21 HU HUS1300062C patent/HUS1300062I1/hu unknown
-
2014
- 2014-06-02 US US14/293,472 patent/US9585873B2/en active Active
-
2015
- 2015-12-07 JP JP2015238531A patent/JP2016094436A/ja active Pending
-
2017
- 2017-01-20 US US15/411,062 patent/US9949954B2/en active Active
- 2017-03-06 JP JP2017042000A patent/JP6337170B2/ja active Active
-
2018
- 2018-03-08 US US15/915,817 patent/US10357479B2/en active Active
- 2018-11-08 HU HUS1800044C patent/HUS1800044I1/hu unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6180425A2 (es) | Antagonista del receptor de angiotensina ii para la prevencion o el tratamiento de enfermedades generalizadas en gatos | |
AU2013221475B2 (en) | Antiviral drugs for treatment of Arenavirus infection | |
ES2526648T3 (es) | Método para mejorar el estrés oxidativo y la memoria de trabajo mediante la administración de pterostilbeno | |
CN109069507B (zh) | 匹莫苯减小心脏尺寸和/或延迟临床症状的发作的用途 | |
ECSP12012048A (es) | Antagonistas del receptor mineralcorticoide no esteroidal | |
JP2014505049A5 (es) | ||
PE20120018A1 (es) | Composicion farmaceutica de linagliptina y 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofuran-3-iloxi)-bencil]-benceno, forma farmaceutica y procedimiento para su preparacion | |
BRPI0714315B8 (pt) | arilamidas substituídas com tetrazol, seu uso e composição farmacêutica que as compreende | |
JP2010077141A5 (es) | ||
JP2011509252A5 (es) | ||
JP2011504903A5 (es) | ||
MX336881B (es) | Compuestos heterociclicos triciclicos. | |
JP2020508339A5 (es) | ||
JP2010536842A5 (es) | ||
CL2011001848A1 (es) | Compuestos derivados de pirimidina fusionada a un heterociclo de 5 miembros; antagonista del receptor de angiotensina ii, agonista del receptor de proliferador de peroxisomas; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades circulatorias tales como hipertension, enfermedad cardiaca, arteriosclerosis, entre otras. | |
JP2009537554A5 (es) | ||
WO2014004676A1 (en) | Use of faah inhibitors as neuroprotective agents in the cns | |
ECSP21091203A (es) | Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa | |
RU2008135692A (ru) | Комбинация органический х-соединений | |
MX2011009506A (es) | Antagonista del receptor mineralcorticoide y metodos de uso. | |
JP2012520302A5 (es) | ||
RU2006117790A (ru) | Применение производного пиразола для получения лекарственного средства, пригодного для профилактики и лечения дислипидемий и заболеваний, связанных с дислипидемиями и/или с ожирением | |
RU2011120347A (ru) | Способ лечения легочной артериальной гипертензии | |
JP2016538295A5 (es) | ||
EP2832357A1 (en) | Selective AT2 receptor agonists for use in treatment of cachexia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Application withdrawn |